top of page

Ymmunobio and EVIIVE announce collaboration to develop advanced liquid biopsy for detecting NPTXR in cancer patients

We are thrilled to announce a groundbreaking partnership between Ymmunobio and EVIIVE to advance the future of cancer diagnostics!

Together, we are developing an innovative liquid biopsy technology using extracellular vesicles (EVs), enhancing precision in disease detection and monitoring. Our joint efforts will leverage Ymmunobio's cutting-edge biotechnological expertise and EVIIVE's advanced diagnostic platforms to create a revolutionary tool in the fight against cancer. 

Ymmunobio and EVIIVE are pioneering advances in diagnostics and oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients.

Stay tuned for more updates as we work towards a brighter, healthier future!

Read the full press release here:


bottom of page